News | March 19, 2009

Drug Information Association Hosts Conference on Cardiovascular Safety, QT/Arrhythmia Assessment in Drug Development

March 19, 2009 - The Drug Information Association (DIA), in cooperation with the Heart Rhythm Society (HRS) and the FDA, will host Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development: Optimizing Drug Development Wednesday, April 29 – Friday, May 1 in Bethesda, MD.

Regulatory, industry, and scientific leaders from around the world will convene to discuss the evolution of drug development, cardiac repolarization, and cardiovascular (CV) safety. The conference will present basic concepts related to the collection, analysis, and interpretation of clinical ECG data, taking into consideration the effect of study design and conduct on these parameters. Sessions will also cover strategies to design a program for QT assessment in all stages of clinical trials and best practices for designing, conducting, analyzing, and interpreting data from a thorough QT/QTc study.

Speakers will also address the strategy behind choosing the optimal timing of the thorough QT study, underlying regulatory thinking in terms of QT prolongation and patient safety, relevant clinical, technological, and statistical issues in the assessment of QT/QTc prolongation in clinical trials. The conference will also address emerging concepts and technologies for QT assessment, such as highly automated measurement methods and their potential role.

"This open forum will discuss the new direction in the development of pharmaceutical agents, practical challenges and possible solutions, ways of challenging the current science, and regulatory approaches,” explains Program Chair Philip Sager, M.D., FACC, FHRS, chief medical officer, CardioDx Inc.

DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and Webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

For more information: www.diahome.org

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init